Second-line therapy for NSCLC in clinical practice: Baseline results of the European SELECTTION observational study

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2661-2672

  Moro Sibilot, Denis ^a   Vergnenegre, Alain ^b   Smit, Egbert F ^c   Toy, Elisabeth ^d   Parente, Barbara ^e   Schmitz, Stephan ^f   Kraaij, Kees ^g   Visseren Grul, Carla ^g   Soldatenkova, Victoria ^h   Arellano, Jorge ⁱ   Leteneux, Claudia ⁱ  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Cluzeau Hospital   (France)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Exeter Mobility Centre   (United Kingdom)

^e Hospital de Vila Nova de Gaia   (Portugal)

^f Medical Oncology and Haematology Clinic   (Germany)

^g Eli Lilly Nederland ^*  (Netherlands)

^h LILLY DEUTSCHLAND GMBH   (Germany)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Chemotherapy; Non small cell lung cancer; Observational study; Second line treatment

Indexed keywords

CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETREATMENT;

EID: 77958114867     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.525489     Document Type: Article

References (26)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-550
5. Reck M, Von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27: 1227-34
6. Pirker R, Szczesna A, Von Pawel J, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008;26:Abstract 3
7. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008;3:430-40
8. Sørensen M., Pijls-Johannesma M., Felip E., et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Onc 2010;21: v120-v125
9. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103
10. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-62
11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
12. Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007;2:397-401
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
14. Azzoli CG, Baker Jr S, Temin S, et al. for the American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66
15. TM Non-Small Cell Lung Cancer V.2.2010. Available at: http:// www.nccn.org/professionals/physician-gls/PDF/nscl.pdf [Last accessed 3 August 2010]
16. McKee M, Britton A, Black N, et al. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999;319:312-15
17. Anderberg MR. Cluster Analysis for Applications. New York: Academic Press, Inc., 1973
18. Ward JH. Hierarchical grouping to optimize an objective function. J Am Stat Assoc 1963;58:236-44
19. Everitt BS. Unresolved problems in cluster analysis. Biometrics 1979; 35:169-81
20. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323-9
21. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53
22. Ettinger DS, Bepler G, Bueno R, et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:548-82
23. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-21
24. Weiss G, Rosell R, Fossella F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18: 453-60
25. Goto Y, Sekine I, Yamada K, et al. Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients. J Thorac Oncol 2008;3:412-16
26. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-63